★ Daily Intelligence Briefings (DIBs)Biotechnology & HealthcareⓁ PharmaceuticalsMarkets Big Pharma Set to Let Biotech Bleed Continue Before Deploying Massive Cash Balances Throughout the past few months, MRP has highlighted significant cash balances among many biopharmaceutical giants. Though hundreds of billions of dollars…McAlinden Research PartnersJune 14, 2022
★ Daily Intelligence Briefings (DIBs)Biotechnology & HealthcareMarkets Discounted Biotech Sellers, Rich Pharma Buyers May Finally Revive M&A Activity in Healthcare The acquisition of biotechnology firms is one of the most common ways big pharma replenishes their pipeline of new drugs. However,…McAlinden Research PartnersMay 12, 2022
★ Daily Intelligence Briefings (DIBs)Biotechnology & Healthcare Evolving COVID Variants May Render Current Treatments Obsolete, Drive Need for New Round of Therapeutics The COVID-19 omicron variant has diminished the efficacy of the US's most prominent antibody treatments. As the genome of this virus constantly…McAlinden Research PartnersJanuary 4, 2022
★ Daily Intelligence Briefings (DIBs)Biotechnology & HealthcareMarkets Biotech, Pharma Cash Piles set to Drive Dealmaking and Buyback Activity in 2022 Most data indicates M&A activity has slowed in the pharmaceutical and biotech industries. However, that may change in 2022 as…McAlinden Research PartnersDecember 22, 2021